Amgen Files NDA For I.V. Rival To Sensipar
This article was originally published in The Pink Sheet Daily
The calcimimetic etelcalcetide could be administered intravenously following dialysis sessions for chronic kidney disease patients with secondary hyperparathyroidism, eliminating the high pill burden associated with Sensipar.
Register for our free email digests: